Use of Japanese encephalitis vaccine in children: Recommendations of the Advisory Committee on Immunization Practices, 2013

Morbidity and Mortality Weekly Report

Volumn 62, Issue 45, 2013, Pages 898-900

  Bocchini Jr , Joseph A ^a   Rubin, Lorry ^a   Fischer, Marc ^a   Hills, Susan L ^a   Staples, J Erin ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VACCINE; JAPANESE ENCEPHALITIS VACCINE;

ADOLESCENT; ADVISORY COMMITTEE; CHILD; HUMAN; IMMUNIZATION; IMMUNOLOGY; INFANT; JAPANESE ENCEPHALITIS; NOTE; PRACTICE GUIDELINE; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; TRAVEL; UNITED STATES;

ADOLESCENT; ADVISORY COMMITTEES; CHILD; CHILD, PRESCHOOL; ENCEPHALITIS, JAPANESE; HUMANS; IMMUNIZATION SCHEDULE; INFANT; JAPANESE ENCEPHALITIS VACCINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; TRAVEL; UNITED STATES; VACCINES, INACTIVATED;

EID: 84887586601     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Note

References (17)

1. CDC. Advisory Committee on Immunization Practices (ACIP): summary report, June 19-20, 2013. Atlanta, GA: US Department of Health and Human Services, CDC; 2013. Available at http://www.cdc. gov/vaccines/acip/meetings/downloads/min-archive/min-jun13.pdf.
2. Ahmed F, Temte J, Campos-Outcalt D, Schunemann H, ACIP Evidence Based Recommendations Work Group. Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC). Vaccine 2011;29:9171-6.
3. CDC. GRADE evidence tables-recommendations in MMWR. Atlanta, GA: US Department of Health and Human Services, CDC; 2013. Available at http://www.cdc.gov/vaccines/acip/recs/grade/table-refs.html.
4. CDC. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2010;59(No. RR-1).
5. Hills SL, Griggs AC, Fischer M. Japanese encephalitis in travelers from nonendemic countries, 1973-2008. Am J Trop Med Hyg 2010;82:930-6.
6. Intercell Biomedical. Ixiaro: package insert and patient information. Livingston, United Kingdom: Intercell Biomedical; 2013. Available at http:// www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ ucm142569.pdf.
7. CDC. Recommendations for use of a booster dose of inactivated Vero cell culture-derived Japanese encephalitis vaccine-Advisory Committee on Immunization Practices, 2011. MMWR 2011;60:661-3.
8. Markoff L. Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines. Vaccine 2000;18(Suppl 2):26-32.
9. Hombach J, Solomon T, Kurane I, Jacobson J, Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines. Vaccine 2005;23:5205-11.
10. Tauber E, Kollaritsch H, Korinek M, et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 2007;370:1847-53.
11. Tauber E, Kollaritsch H, von Sonnenburg F, et al. Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J Infect Dis 2008;198:493-9.
12. Dubischar-Kastner K, Kaltenboeck A, Klingler A, Jilma B, Schuller E. Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine, Ixiaro (IC51), in 6 months of follow-up. Vaccine 2010;28:6463-9.
13. Schuller E, Klingler A, Dubischar-Kastner K, Dewasthaly S, Muller Z. Safety profile of the Vero cell-derived Japanese encephalitis virus (JEV) vaccine Ixiaro. Vaccine 2011;29:8669-76.
14. Fischer M. Japanese encephalitis (JE) vaccine for U.S. travelers. Presentation to the Advisory Committee on Immunization Practices, Atlanta, GA, February 20, 2013. Available at http://www.cdc.gov/vaccines/ acip/meetings/downloads/slides-feb-2013/02-je-vaccine-fischer.pdf.
15. Dubischar-Kastner K. Pediatric data for Ixiaro: Japanese encephalitis vaccine, inactivated, adsorbed. Presentation to the Advisory Committee on Immunization Practices, Atlanta, GA, June 19, 2013. Available at http://www.cdc.gov/vaccines/ acip/meetings/downloads/slides-jun-2013/02-je-dubischar-kastner.pdf.
16. Food and Drug Administration. Clinical review: Ixiaro. Silver Spring, MD: Food and Drug Administration; 2013. Available at http://www.fda.gov/downloads/ biologicsbloodvaccines/vaccines/approvedproducts/ucm354012.pdf.
17. Kaltenböck A, Dubischar-Kastner K, Schuller E, Datla M, Klade CS, Kishore TS. Immunogenicity and safety of Ixiaro (IC51) in a phase II study in healthy Indian children between 1 and 3 years of age. Vaccine 2010;28:834-9.